Enliven Therapeutics
ELVN
41.36
-1.03
-2.43%
Enliven Therapeutics
US · ELVN
#2416 by market cap
Listed 1970
41.36
-1.03
-2.43%
Live - 5344 symbols - heartbeat 224s ago
· 2026-10-08 08:20
Pre-market
43.00
+3.97%
After-hours
41.36
0.00%
Overnight
41.74
+0.92%
- Market cap
- 3.03B
- P/E (TTM)i
- -25.07
- P/Bi
- 3.39
- EPSi
- -1.83
- Div yieldi
- 0.00%
- 52W posi
- 56%
Reader sentiment
Are you bullish or bearish on ELVN?
Anonymous reader poll. Unscientific, not investment advice.
Revenue annual, last 6 years
Income statement
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 1.08M | 4.29M | 7.77M | 18.96M | 23.78M | 33.80M |
| Research & development | 8.24M | 20.47M | 31.02M | 64.57M | 80.78M | 85.86M |
| Operating profit | -9.32M | -24.76M | -38.79M | -83.53M | -104.55M | -119.66M |
| Pretax profit | -18.97M | -24.74M | -37.66M | -71.58M | -88.79M | -103.69M |
| Tax | -- | -- | -- | 0 | 232.00K | 0 |
| Net profit | -18.97M | -24.74M | -37.66M | -71.58M | -89.02M | -103.69M |
| Basic EPS | 0 | -1 | -1 | -2 | -2 | -2 |
| Diluted EPS | -0.46 | -0.60 | -0.92 | -2.01 | -1.89 | -1.83 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 6.80M | 7.09M | 6.87M | 13.04M | 7.14M | 8.21M |
| Research & development | 24.90M | 21.49M | 18.23M | 21.25M | 20.69M | 29.00M |
| Operating profit | -31.69M | -28.58M | -25.10M | -34.29M | -27.82M | -37.21M |
| Pretax profit | -28.54M | -25.34M | -20.15M | -29.67M | -23.63M | -32.49M |
| Tax | -- | -- | 0 | 0 | -- | -- |
| Net profit | -28.54M | -25.34M | -20.15M | -29.67M | -23.63M | -32.49M |
| Basic EPS | -1 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.57 | -0.49 | -0.32 | -0.48 | -0.38 | -0.49 |
Balance sheet
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total current assets | 130.59M | 110.67M | 77.75M | 266.15M | 318.13M | 474.88M |
| Cash & ST investments | 130.37M | 110.02M | 75.54M | 253.15M | 313.44M | 462.62M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 131.00M | 113.33M | 83.30M | 271.87M | 325.76M | 476.17M |
| Total current liabilities | 1.48M | 5.75M | 9.72M | 25.89M | 15.92M | 16.57M |
| Short-term debt | 105.00K | 159.00K | 323.00K | 335.00K | -- | 399.00K |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 151,307,000.00 | 156,216,000.00 | 160,123,000.00 | 25,961,000.00 | 15,915,000.00 | 16,568,000.00 |
| Total equity | -20.30M | -42.89M | -76.83M | 245.91M | 309.85M | 459.60M |
| Retained earnings | -20.46M | -45.20M | -82.86M | -154.45M | -243.47M | -347.17M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 294.32M | 495.62M | 482.68M | 474.88M | 463.14M | 907.34M |
| Cash & ST investments | 289.56M | 490.50M | 477.57M | 462.62M | 452.40M | 895.16M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 302.57M | 503.89M | 490.88M | 476.17M | 464.85M | 910.22M |
| Total current liabilities | 13.97M | 15.21M | 14.65M | 16.57M | 11.49M | 14.16M |
| Short-term debt | 365.00K | 376.00K | 387.00K | 399.00K | 302.00K | 597.00K |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 14,274,000.00 | 15,415,000.00 | 14,753,000.00 | 16,568,000.00 | 11,487,000.00 | 15,074,000.00 |
| Total equity | 288.30M | 488.47M | 476.12M | 459.60M | 453.37M | 895.15M |
| Retained earnings | -272.02M | -297.35M | -317.50M | -347.17M | -370.79M | -403.28M |
Cash flow
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -8.53M | -19.13M | -32.08M | -61.27M | -73.19M | -70.30M |
| Depreciation & amortization | 45.00K | 115.00K | 215.00K | 297.00K | 317.00K | 263.00K |
| Free cash flow | -8.99M | -19.33M | -32.69M | -61.42M | -73.24M | -70.46M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 140.00K | 690.00K | -- | 0 | 128.88M | 216.17M |
| Ending cash balance | 130.42M | 110.08M | 75.59M | 100.20M | 124.17M | 98.90M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -24.13M | -17.06M | -13.28M | -15.84M | -19.29M | -18.53M |
| Depreciation & amortization | 74.00K | 81.00K | 62.00K | 46.00K | 14.00K | 7.00K |
| Free cash flow | -24.15M | -17.20M | -13.28M | -15.84M | -19.29M | -18.63M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -458.00K | 0 | -- | -- |
| Ending cash balance | 101.71M | 119.44M | 101.73M | 98.90M | 132.18M | 135.51M |
Returns & efficiency
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -- | -84.67 | -32.04 | -26.95 |
| ROA %i | -14.48 | -20.25 | -38.31 | -40.31 | -29.79 | -25.86 |
| ROIC %i | -- | -- | -- | -98.45 | -36.27 | -31.08 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 88.35 | 19.24 | 8.00 | 10.28 | 19.99 | 28.66 |
| Quick ratioi | 88.20 | 19.12 | 7.78 | 9.78 | 19.69 | 27.92 |
| Debt / assetsi | 0.08 | 0.14 | 0.39 | 0.12 | 0.00 | 0.08 |
| LT debt / equityi | -- | -- | -- | -- | -- | -- |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | 0.00 | 0.00 | 0.00 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -31.30 | -25.26 | -25.43 | -26.95 | -26.64 | -15.31 |
| ROA %i | -29.39 | -24.12 | -24.41 | -25.86 | -25.74 | -14.98 |
| ROIC %i | -36.16 | -28.76 | -29.36 | -31.08 | -31.20 | -17.97 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 21.06 | 32.58 | 32.95 | 28.66 | 40.32 | 64.07 |
| Quick ratioi | 20.72 | 32.25 | 32.60 | 27.92 | 39.38 | 63.21 |
| Debt / assetsi | 0.12 | 0.12 | 0.08 | 0.08 | 0.07 | 0.07 |
| LT debt / equityi | -- | 0.04 | -- | -- | -- | -- |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Quote time 2026-10-08 08:20:04 · For reference only, not investment advice and not tailored to your situation.